4.7 Article

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals

Journal

ALZHEIMERS & DEMENTIA
Volume 18, Issue 7, Pages 1383-1395

Publisher

WILEY
DOI: 10.1002/alz.12487

Keywords

Alzheimer's disease; Alzheimer's disease signature; apolipoprotein E epsilon 2 carrier; brain maintenance; brain morphology; brain reserve; cognitive reserve; magnetic resonance; multi-site; resilience signature

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI
  2. National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. BristolMyers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd.
  20. Genentech, Inc.
  21. Fujirebio
  22. GE Healthcare
  23. IXICO Ltd.
  24. Janssen Alzheimer Immunotherapy Research & Development, LLC
  25. Johnson & Johnson Pharmaceutical Research & Development LLC
  26. Lumosity
  27. Lundbeck
  28. Merck Co., Inc.
  29. Meso Scale Diagnostics, LLC
  30. NeuroRx Research
  31. Neurotrack Technologies
  32. Novartis Pharmaceuticals Corporation
  33. Pfizer Inc.
  34. Piramal Imaging
  35. Servier
  36. Takeda Pharmaceutical Company
  37. Transition Therapeutics
  38. Canadian Institutes of Health Research
  39. la Caixa Foundation [100010434, LCF/PR/GN17/50300004]
  40. Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government [2017-SGR-892]
  41. Spanish Ministry of Science, Innovation and Universities-Spanish State Research Agency [RYC2018-026053-I]
  42. NIHR biomedical research centre at UCLH
  43. Swedish Research Council [2019-02075, 2016-02282, 2016-00906]
  44. Swedish state government
  45. Swedish county councils, the ALF-agreement [ALF 716681, ALFGBG-81392, ALFGBG-771071]
  46. Alzheimerfonden
  47. Hjarnfonden
  48. Swedish Foundation for Strategic Research (SSF)
  49. Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro)
  50. Stockholm County Council
  51. Karolinska Institutet
  52. Center for Innovative Medicine (CIMED)
  53. Swedish Alzheimer Foundation
  54. Swedish Brain Foundation
  55. Ake Wiberg Foundation
  56. Demensfonden
  57. Stiftelsen Olle Engkvist Byggmastare
  58. Birgitta och Sten Westerberg
  59. Stiftelsen Loo och Hans Ostermans
  60. Stiftelsen Gun och Bertil Stohnes
  61. Stiftelsen Sigurd och Elsa Goljes Minne
  62. Spanish Ministry of Economy, and Competitiveness [RYC-2013-13054]
  63. Knut and Alice Wallenberg foundation [2017-0383]
  64. Marianne and Marcus Wallenberg foundation [2015.0125]
  65. Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
  66. Swedish Alzheimer Foundation [AF939932]
  67. Swedish Brain Foundation [FO2019-0326]
  68. Parkinson foundation of Sweden [1280/20]
  69. Skane University Hospital Foundation [2020-O000028]
  70. Regionalt Forskningsstod [2020-0314]
  71. Swedish federal government under the ALF agreement [2018Projekt0279]
  72. Vinnova [2016-02282] Funding Source: Vinnova
  73. Swedish Research Council [2016-02282, 2019-02075] Funding Source: Swedish Research Council

Ask authors/readers for more resources

Carrying the APOE ε2 allele is associated with larger gray matter volumes in brain regions affected by AD, providing additional protection against cognitive decline. Homozygotes for the ε2 allele exhibit larger GM volumes in regions related to successful aging.
Introduction: Harboring two copies of the apolipoprotein E (APOE) epsilon 2 allele strongly protects against Alzheimer's disease (AD). However, the effect of this genotype on gray matter (GM) volume in cognitively unimpaired individuals has not yet been described. Methods: Multicenter brain magnetic resonance images (MRIs) from cognitively unimpaired epsilon 2 homozygotes were matched (1:1) against all other APOE genotypes for relevant confounders (n = 223). GM volumes of epsilon 2 genotypic groups were compared to each other and to the reference group (APOE epsilon 3/epsilon 3). Results: Carrying at least one epsilon 2 allele was associated with larger GM volumes in brain areas typically affected by AD and also in areas associated with cognitive resilience. APOE epsilon 2 homozygotes, but not APOE epsilon 2 heterozygotes, showed larger GM volumes in areas related to successful aging. Discussion: In addition to the known resistance against amyloid-beta deposition, the larger GM volumes in key brain regions may confer APOE epsilon 2 homozygotes additional protection against AD-related cognitive decline.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available